Comparative Pharmacology
Head-to-head clinical analysis: NAVANE versus PERSERIS KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAVANE versus PERSERIS KIT.
NAVANE vs PERSERIS KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene neuroleptic; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic blocking, and sedative effects.
Risperidone, the active component of PERSERIS, is an atypical antipsychotic with antagonist activity at dopamine D2 and serotonin 5-HT2A receptors. It also binds to α1-adrenergic, α2-adrenergic, and histamine H1 receptors.
Oral: 10-20 mg three times daily; maximum 160 mg/day. IM (acute): 5-10 mg every 4-6 hours; maximum 30 mg/day.
Subcutaneous injection: 90 mg every 28 days for maintenance treatment of schizophrenia.
None Documented
None Documented
Terminal elimination half-life is approximately 20-24 hours, allowing for once-daily dosing. Steady-state reached in 4-5 days.
Terminal elimination half-life is approximately 15 days (range 10-20 days) for the extended-release injectable formulation, reflecting slow release from the depot and sustained plasma concentrations.
Primarily hepatic metabolism; approximately 20-30% excreted renally as metabolites, <1% unchanged. Biliary/fecal excretion accounts for ~50% of metabolites.
Primarily hepatic metabolism via CYP2D6 and CYP3A4; approximately 30-40% of a dose is excreted in urine as metabolites, with less than 1% as unchanged drug. Biliary/fecal elimination accounts for about 60-70%.
Category C
Category C
Antipsychotic, Typical
Antipsychotic